Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00471588
Status:
COMPLETED
Last Update Posted:
2014-09-15
First Post:
2007-05-08
Brief Title:
Characterize The Modulatory Effects Of Dopamine D2D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Dopamine D2D3 Receptor Agonist and Antagonist Drug Effects on Fronto-striatal Systems Related to Compulsive Behaviour in Healthy Volunteers and Patients With Addictive and Compulsive Disorders
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
3 groups of subjects healthy controls OCD subjects and stimulant-dependent subjects will receive pramipexole 15 mg single dose amisulpride 400 mg single dose or placebo in a cross-over double-blind placebo-controlled design
Effects of compulsive behaviour will be assessed using fMRI and cognitive testing
Assess biomarkers including cardiovascular responses and plasma levels All groups studied on 3 separate occasions following screening with at least a week intervening between consecutive assessments The procedures to be adopted for study assessment will be identical on each occasion
Effects of compulsive behaviour will be assessed using fMRI and cognitive testing
Assess biomarkers including cardiovascular responses and plasma levels All groups studied on 3 separate occasions following screening with at least a week intervening between consecutive assessments The procedures to be adopted for study assessment will be identical on each occasion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None